PHASE III AXIS TRIAL OF AXITINIB VERSUS SORAFENIB IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA: ASIAN SUBGROUP ANALYSIS

被引：0

作者：

Uemura, H. ^{[1
]}

Ou, Y. -C. ^{[2
]}

Lim, H. Y. ^{[3
]}

Tomita, Y. ^{[4
]}

Ueda, T. ^{[5
]}

Menon, H. ^{[6
]}

Chung, J. ^{[7
]}

Guo, J. ^{[8
]}

Tarazi, J. ^{[9
]}

Kim, S. ^{[9
]}

Naito, S. ^{[10
]}

Akaza, H. ^{[11
]}

机构：

[1] Kinki Univ, Sch Med, Dept Urol, Osaka 589, Japan

[2] Taichung Vet Gen Hosp, Dept Surg, Taichung, Taiwan

[3] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Hematol Oncol, Seoul, South Korea

[4] Yamagata Univ, Fac Med, Dept Urol, Yamagata 990, Japan

[5] Chiba Canc Ctr, Dept Urol, Chiba 2608717, Japan

[6] Tata Mem Hosp, Dept Med Oncol, Bombay 400012, Maharashtra, India

[7] Natl Canc Ctr, Urol Oncol Clin, Gyeonggi Do, South Korea

[8] Peking Univ, Canc Hosp, Dept Renal Canc & Melanoma, Beijing 100871, Peoples R China

[9] Pfizer Oncol, La Jolla, CA USA

[10] Kyushu Univ, Grad Sch Med Sci, Dept Urol, Fukuoka 812, Japan

[11] Univ Tokyo, Res Ctr Adv Sci & Technol, Tokyo, Japan

来源：

ANNALS OF ONCOLOGY | 2012年 / 23卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：6 / 6

页数：1

共 50 条

[41] SUBGROUP ANALYSIS OF ASIAN PATIENTS IN THE PHASE III TRIAL (GRID) OF REGORAFENIB IN PRETREATED METASTATIC GIST
Kang, Y. -K.
Xu, J.
Komatsu, Y.
Im, S. -A.
Li, J.
Nishida, T.
Quek, R.
Kappeler, C.
Kuss, I.
Demetri, G. D.
Takimoto, R.
ANNALS OF ONCOLOGY, 2013, 24
[42] Comparative efficacy of axitinib versus sorafenib for advanced renal cell carcinoma
不详
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2012, 1 (01) : 11 - 12
[43] Re: Tivozanib versus Sorafenib as Initial Targeted Therapy for Patients with Metastatic Renal Cell Carcinoma: Results from a Phase III Trial Editorial Comment
Laguna, M. Pilar
JOURNAL OF UROLOGY, 2014, 192 (04): : 1079 - 1079
[44] TRAXAR study: a randomized phase 2 trial of axitinib and TRC105 versus axitinib alone in patients with advanced or metastatic renal cell carcinoma (mRCC)
Choueiri, T.
Agarwal, N.
Ho, T.
Pal, S. K.
Seon, B.
Jivani, M.
Adams, B.
Shazer, R.
Theuer, C.
ANNALS OF ONCOLOGY, 2016, 27
[45] TRAXAR study: a randomized phase 2 trial of axitinib and TRC105 versus AXitinib alone in patients with advanced or metastatic renal cell carcinoma (mRCC)
Choueiri, Toni K.
Agarwal, Neeraj
Ho, Thai H.
Pachynski, Russell
Pal, Sumanta
Ryan, Christopher W.
Vaena, Daniel
Lara, Primo
Lawler, William
Posadas, Edwin
Sonpavde, Guru P.
Wang, Peng
Gabrail, Nashat
Hammers, Hans-Joerg
Merchan, Jaime
Olencki, Thomas
Redman, Bruce
Sean, Ben K.
Adams, Bonne J.
Theuer, Charles P.
BJU INTERNATIONAL, 2015, 116 : 5 - 6
[46] AXITINIB VS SORAFENIB FOR ADVANCED RENAL CELL CARCINOMA: PHASE III OVERALL SURVIVAL RESULTS AND ANALYSIS OF PROGNOSTIC FACTORS
Motzer, R. J.
Escudier, B.
Tomczak, P.
Negrier, S.
Gore, M. E.
Tarazi, J.
Hariharan, S.
Rosbrook, B.
Kim, S.
Rini, B. I.
ANNALS OF ONCOLOGY, 2012, 23 : 262 - 262
[47] Safety of axitinib and sorafenib monotherapy for patients with renal cell carcinoma:a meta-analysis
Fei Qin
Hao Yu
Changrong Xu
Huihui Chen
Jianling Bai
TheJournalofBiomedicalResearch, 2018, 32 (01) : 30 - 38
[48] Subgroup Analysis of East Asian Patients in the Phase III REVEL Trial
Kang, Jin-Hyoung
Park, Keunchil
Kim, Joo-Hang
Cho, Eun Kyung
Shih, Jin-Yuan
Zimmermann, Annamaria H.
Lee, Pablo
Alexandris, Ekaterine
Puri, Tarun
Orlando, Mauro
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S323 - S323
[49] Subgroup Analysis of East Asian Patients in the Phase III PROCLAIM Trial
Wang, Luhua
Wu, Yi-Long
Lu, Shun
Deng, Lei
Ahn, Myung-Ju
Hsu, Feng-Ming
Iscoe, Neill
Hossain, Anwar
Puri, Tarun
Zhang, Pinghai
Orlando, Mauro
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S576 - S576
[50] ATLAS trial of adjuvant axitinib in patients with renal cell carcinoma: subgroup analyses with focus on axitinib dosing and racial groups
Quinn, D., I
Ng, C. F.
Grande, E.
Kwon, T. G.
Linke, R.
Lee, J-L
Rosbrook, B.
Thakur, M. N.
Eto, M.
Gross-Goupil, M.
ESMO OPEN, 2021, 6 (03)

← 1 2 3 4 5 →